47 related articles for article (PubMed ID: 9352324)
41. Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?
Mims A; Stuart RK
Curr Hematol Malig Rep; 2013 Jun; 8(2):156-62. PubMed ID: 23640069
[TBL] [Abstract][Full Text] [Related]
42. Evolving clinical strategies: innovative approaches to the use of mitoxantrone--introduction.
Powles TJ
Eur J Cancer Care (Engl); 1997 Dec; 6(4 Suppl):1-3. PubMed ID: 9460335
[TBL] [Abstract][Full Text] [Related]
43. Mitoxantrone in the treatment of acute myelogenous leukemia: a review.
Thomas X; Archimbaud E
Hematol Cell Ther; 1997 Aug; 39(4):63-74. PubMed ID: 9352324
[TBL] [Abstract][Full Text] [Related]
44. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
Ann Hematol; 2018 Jul; 97(7):1115-1153. PubMed ID: 29680875
[TBL] [Abstract][Full Text] [Related]
45. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.
Dunn CJ; Goa KL
Drugs Aging; 1996 Aug; 9(2):122-47. PubMed ID: 8820798
[TBL] [Abstract][Full Text] [Related]
46. Etoposide in acute leukemia. Past experience and future perspectives.
Ho AD; Brado B; Haas R; Hunstein W
Cancer; 1991 Jan; 67(1 Suppl):281-4. PubMed ID: 1984828
[TBL] [Abstract][Full Text] [Related]
47. Treatment of relapsed acute myeloid leukaemia.
Kell J
Rev Recent Clin Trials; 2006 May; 1(2):103-11. PubMed ID: 18473961
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
